Breadcrumbs

Colorectal - oncology

Adjuvant and Neoadjuvant

Protocol Administration at chemotherapy unit level Review date
Colorectal adjuvant capecitabine Low September 2022
Colorectal adjuvant CAPOX (XELOX) (Capecitabine and Oxaliplatin) Medium March 2020
Colorectal adjuvant de Gramont (modified) (fluorouracil and leucovorin) Low September 2020
Colorectal adjuvant FOLFOX6 (Modified) (fluorouracil leucovorin oxaliplatin) Medium 2 March 2021
Colorectal adjuvant QUASAR (Modified) fluorouracil leucovorin weekly Low September 2022
Colorectal adjuvant Roswell Park (modified) fluorouracil and leucovorin weekly Low March 2020

Metastatic

Protocol Administration at chemotherapy unit level Review date
Colorectal metastatic capecitabine Low September 2020
Colorectal metastatic capecitabine and bevacizumab Low March 2021
Colorectal metastatic CAPIRI (XELIRI) (capecitabine irinotecan) Medium September 2022
Colorectal metastatic CAPIRI (XELIRI) (capecitabine irinotecan) and bevacizumab Medium March 2020
Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) Medium September 2020
Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) and bevacizumab Medium March 2021
Colorectal metastatic cetuximab Low September 2022
Colorectal metastatic cetuximab (two weekly) Low March 2020
Colorectal metastatic cetuximab (weekly) and irinotecan (two weekly) Medium September 2020
Colorectal metastatic cetuximab and irinotecan (two weekly) Medium March 2021
Colorectal metastatic de Gramont (modified) (fluorouracil and leucovorin) Low2 September 2022
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) Medium 2 March 2020
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and bevacizumab Medium 2 September 2020
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab Medium March 2021
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and panitumumab Medium September 2022
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab (two weekly) Medium March 2020
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) Medium 2 September 2020
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and bevacizumab Medium 2 March 2021
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and cetuximab Medium 2 March 2021
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and panitumumab Medium September 2022
Colorectal metastatic irinotecan three weekly
Medium March 2022
Colorectal metastatic irinotecan 2-weekly
(for information on this protocol please contact the SA Health Cancer Drug Committee)
Medium December 2021
Colorectal metastatic irinotecan and panitumumab
(for information on this protocol please contact the SA Health Cancer Drug Committee)
Medium December 2021
Colorectal metastatic panitumumab Low September 2020
Colorectal metastatic QUASAR (modified) fluorouracil and leucovorin weekly Low March 2021
Colorectal metastatic raltitrexed Medium September 2022
Colorectal metastatic regorafenib Low March 2021
Colorectal metastatic Roswell Park (modified) fluorouracil and leucovorin weekly Low September 2020
Colorectal metastatic Roswell Park (modified) fluorouracil leucovorin weekly and bevacizumab Low March 2021
Colorectal metastatic trifluridine/tipiracil Medium March 2022

Anal

Protocol Administration at chemotherapy unit level Review date
Anal definitive cISplatin and fluorouracil chemoradiation Medium 3 September 2022
Anal definitive mitomycin and capecitabine chemoradiation Medium 3 March 2020
Anal definitive mitomycin and fluorouracil chemoradiation Medium 2, 3 September 2020

Rectal

Protocol Administration at chemotherapy unit level Review date
Rectal locally advanced capecitabine chemoradiation Medium 3 March 2021
Rectal locally advanced fluorouracil (protracted Infusion) chemoradiation Medium 2, 3 September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top